New assessment and treatment opportunities for people with severe asthma promise better outcomes
“It’s been a long time coming, but I feel great now.” “I feel like I’ve got my life back.” These are statements made by patients with severe asthma who have had positive responses to targeted monoclonal antibody therapy for asthma. Both patients have severe refractory eosinophilic asthma and have experienced many years of persistent symptoms despite daily maintenance prednisone. On monoclonal antibody therapy, they achieved complete symptom control and significant prednisone reduction.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.